A. B. Ryerson, C. R. Eheman, and S. F. Altekruse, Annual report to the nation on the status of cancer, 1975-2012, featuring the increasing incidence of liver cancer, Cancer, vol.122, pp.1312-1337, 2016.

N. Fujiwara, S. L. Friedman, N. Goossens, and Y. Hoshida, Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine, J Hepatol, vol.68, pp.526-549, 2018.

T. Boldanova, A. Suslov, M. H. Heim, and A. Necsulea, Transcriptional response to hepatitis C virus infection and interferon-alpha treatment in the human liver, EMBO Mol Med, vol.9, pp.816-834, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02049665

H. B. El-serag, F. Kanwal, P. Richardson, and J. Kramer, Risk of hepatocellular carcinoma after sustained virological response in veterans with hepatitis C virus infection, Hepatology, vol.64, pp.130-137, 2016.

F. Kanwal, J. Kramer, and S. M. Asch, Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents, Gastroenterology, vol.153, pp.996-1005, 2017.

A. J. Van-der-meer, J. J. Feld, and H. Hofer, Risk of cirrhosisrelated complications in patients with advanced fibrosis following hepatitis C virus eradication, J Hepatol, vol.66, pp.485-493, 2017.

S. P. Sajankila, P. V. Manthena, and S. Adhikari, Suppression of tumor suppressor Tsc2 and DNA repair glycosylase Nth1 during spontaneous liver tumorigenesis in Long-Evans Cinnamon rats, Mol Cell Biochem, vol.338, pp.233-239, 2010.

Y. Zhang, T. Liu, and C. A. Meyer, Model-based analysis of ChIP-Seq (MACS)

, Genome Biol, vol.9, p.137, 2008.

S. Nakagawa, L. Wei, and W. M. Song, Molecular liver cancer prevention in cirrhosis by organ transcriptome analysis and lysophosphatidic acid pathway inhibition, Cancer Cell, vol.30, pp.879-890, 2016.
URL : https://hal.archives-ouvertes.fr/inserm-02312659

Y. Hoshida, A. Villanueva, and A. Sangiovanni, Prognostic gene expression signature for patients with hepatitis Crelated early-stage cirrhosis, Gastroenterology, vol.144, pp.1024-1030, 2013.

P. A. Jones, J. Issa, and S. Baylin, Targeting the cancer epigenome for therapy, Nat Rev Genet, vol.17, p.630, 2016.

M. Y. Cai, J. H. Hou, and H. L. Rao, High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients, Mol Med, vol.17, pp.12-20, 2011.

T. Uchida, N. Hiraga, and M. Imamura, Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, Virus Res, vol.213, pp.62-68, 2016.

C. Schmidl, A. F. Rendeiro, N. C. Sheffield, and C. Bock, ChIPmentation: fast, robust, low-input ChIP-seq for histones and transcription factors, Nat Methods, vol.12, pp.963-965, 2015.

J. Harrow, F. Denoeud, and A. Frankish, GENCODE: producing a reference annotation for ENCODE, Genome Biol, vol.7, issue.1, pp.41-49, 2006.

A. Subramanian, P. Tamayo, and V. K. Mootha, Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles, Proc Natl Acad Sci U S A, vol.102, pp.15545-15550, 2005.

Y. Hoshida, A. Villanueva, and M. Kobayashi, Gene expression in fixed tissues and outcome in hepatocellular carcinoma, N Engl J Med, vol.359, pp.1995-2004, 2008.

E. Calo and J. Wysocka, Modification of enhancer chromatin: what, how, and why?, Mol Cell, vol.49, pp.825-837, 2013.

T. Rohrbach, M. Maceyka, and S. Spiegel, Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology, Crit Rev Biochem Mol Biol, vol.52, pp.543-553, 2017.

H. Cai, X. Xie, and L. Ji, Sphingosine kinase 1: A novel independent prognosis biomarker in hepatocellular carcinoma, Oncol Lett, vol.13, pp.2316-2322, 2017.

N. Van-renne, R. Suarez, A. A. Duong, and F. , miR135a-5p-mediated downregulation of protein tyrosine phosphatase receptor delta is a candidate driver of HCVassociated hepatocarcinogenesis, Gut, vol.67, pp.953-962, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01837106

L. Y. King, C. Canasto-chibuque, and K. B. Johnson, A genomic and clinical prognostic index for hepatitis Crelated early-stage cirrhosis that predicts clinical deterioration, Gut, vol.64, pp.1296-1302, 2015.

D. Hanahan and R. A. Weinberg, Hallmarks of cancer: the next generation, Cell, vol.144, pp.646-674, 2011.

Y. Okamoto, K. Shinjo, and Y. Shimizu, Hepatitis virus infection affects DNA methylation in mice with humanized livers, Gastroenterology, vol.146, pp.562-572, 2014.

A. Hayashi, N. Yamauchi, and J. Shibahara, Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior, PLoS One, vol.9, p.91330, 2014.

A. J. Ruthenburg, C. D. Allis, and J. Wysocka, Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark, Mol Cell, vol.25, pp.15-30, 2007.

R. S. Scott, Epstein-Barr virus: a master epigenetic manipulator, Curr Opin Virol, vol.26, pp.74-80, 2017.

A. El-osta, D. Brasacchio, and D. Yao, Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia, J Exp Med, vol.205, pp.2409-2417, 2008.

E. Moran-salvador and J. Mann, Epigenetics and liver fibrosis, Cell Mol Gastroenterol Hepatol, vol.4, pp.125-134, 2017.

W. K. Bae, K. Kang, and J. H. Yu, The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration, FASEB J, vol.29, pp.1653-1662, 2015.

G. Richtig, A. Aigelsreiter, and D. Schwarzenbacher, SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types, PLoS One, vol.12, p.187814, 2017.

J. Chen, Y. Qi, and Y. Zhao, Deletion of sphingosine kinase 1 inhibits liver tumorigenesis in diethylnitrosaminetreated mice, Oncotarget, vol.9, pp.15635-15649, 2018.

E. Kim, D. Kim, and J. Lee, Capicua suppresses hepatocellular carcinoma progression by controlling the ETV4-MMP1 axis, Hepatology, vol.67, pp.2287-2301, 2018.

C. L. Wilson, D. A. Mann, and L. A. Borthwick, Epigenetic reprogramming in liver fibrosis and cancer, Adv Drug Deliv Rev, vol.121, pp.124-132, 2017.

C. Tateno, Y. Kawase, and Y. Tobita, Generation of novel chimeric mice with humanized livers by using hemizygous cDNA-uPA/SCID mice, PLoS One, vol.10, p.142145, 2015.

D. Kim, B. Langmead, and S. L. Salzberg, HISAT: a fast spliced aligner with low memory requirements, NatMethods, vol.12, pp.357-360, 2015.

H. Li, A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data, Bioinformatics, vol.27, pp.2987-2993, 2011.

A. R. Quinlan and I. M. Hall, BEDTools: a flexible suite of utilities for comparing genomic features, Bioinformatics, vol.26, pp.841-842, 2010.

Y. Zhang, T. Liu, and C. A. Meyer, Model-based analysis of ChIP-Seq (MACS)

, Genome Biol, vol.9, p.137, 2008.

M. Martin, Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet.journal, 2011.

J. Harrow, F. Denoeud, and A. Frankish, GENCODE: producing a reference annotation for ENCODE

, Genome Biol, vol.7, issue.1, pp.41-49, 2006.

M. D. Robinson, D. J. Mccarthy, and G. K. Smyth, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics, vol.26, pp.139-140, 2010.

P. Shannon, A. Markiel, and O. Ozier, Cytoscape: a software environment for integrated models of biomolecular interaction networks, Genome Res, vol.13, pp.2498-2504, 2003.

D. Hatoum, N. Haddadi, and Y. Lin, Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget, Oncotarget, vol.8, pp.36898-36929, 2017.

, Author names in bold designate shared co-first authorship, 2019.

, HCV-Induced Epigenetic Changes Persist After SVR 2329, p.2